Avinger, Inc. (AVGR)
USD 0.49
(-3.35%)
USD 0.49
(-3.35%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.65 Million USD | -7.51% |
| 2022 | 8.27 Million USD | -18.33% |
| 2021 | 10.13 Million USD | 15.63% |
| 2020 | 8.76 Million USD | -4.05% |
| 2019 | 9.13 Million USD | 15.36% |
| 2018 | 7.91 Million USD | -20.32% |
| 2017 | 9.93 Million USD | -48.3% |
| 2016 | 19.21 Million USD | 79.35% |
| 2015 | 10.71 Million USD | -4.46% |
| 2014 | 11.21 Million USD | -13.51% |
| 2013 | 12.96 Million USD | 51.45% |
| 2012 | 8.56 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 1.84 Million USD | -0.65% |
| 2024 Q1 | 1.85 Million USD | -2.47% |
| 2023 Q4 | 1.9 Million USD | 4.9% |
| 2023 FY | 7.65 Million USD | -7.51% |
| 2023 Q2 | 2.04 Million USD | 8.1% |
| 2023 Q1 | 1.88 Million USD | -5.65% |
| 2023 Q3 | 1.81 Million USD | -10.98% |
| 2022 FY | 8.27 Million USD | -18.33% |
| 2022 Q4 | 2 Million USD | -11.15% |
| 2022 Q3 | 2.25 Million USD | 5.63% |
| 2022 Q2 | 2.13 Million USD | 12.92% |
| 2022 Q1 | 1.88 Million USD | -21.43% |
| 2021 FY | 10.13 Million USD | 15.63% |
| 2021 Q2 | 2.8 Million USD | 9.5% |
| 2021 Q3 | 2.36 Million USD | -15.56% |
| 2021 Q1 | 2.55 Million USD | -6.33% |
| 2021 Q4 | 2.4 Million USD | 1.56% |
| 2020 Q2 | 1.46 Million USD | -35.16% |
| 2020 Q3 | 2.3 Million USD | 57.03% |
| 2020 Q1 | 2.26 Million USD | -11.75% |
| 2020 Q4 | 2.73 Million USD | 18.68% |
| 2020 FY | 8.76 Million USD | -4.05% |
| 2019 Q2 | 2.31 Million USD | 26.03% |
| 2019 FY | 9.13 Million USD | 15.36% |
| 2019 Q4 | 2.56 Million USD | 6.31% |
| 2019 Q3 | 2.41 Million USD | 3.92% |
| 2019 Q1 | 1.84 Million USD | -9.27% |
| 2018 Q3 | 2.02 Million USD | -1.85% |
| 2018 FY | 7.91 Million USD | -20.32% |
| 2018 Q4 | 2.02 Million USD | 0.4% |
| 2018 Q2 | 2.05 Million USD | 13.76% |
| 2018 Q1 | 1.8 Million USD | -5.44% |
| 2017 Q2 | 2.45 Million USD | -29.56% |
| 2017 Q4 | 1.91 Million USD | -7.63% |
| 2017 Q1 | 3.49 Million USD | -25.39% |
| 2017 FY | 9.93 Million USD | -48.3% |
| 2017 Q3 | 2.07 Million USD | -15.78% |
| 2016 Q4 | 4.67 Million USD | -11.98% |
| 2016 FY | 19.21 Million USD | 79.35% |
| 2016 Q3 | 5.31 Million USD | 13.59% |
| 2016 Q2 | 4.68 Million USD | 3.11% |
| 2016 Q1 | 4.53 Million USD | 58.87% |
| 2015 FY | 10.71 Million USD | -4.46% |
| 2015 Q2 | 3.04 Million USD | 45.93% |
| 2015 Q1 | 2.08 Million USD | -32.05% |
| 2015 Q4 | 2.85 Million USD | 5.0% |
| 2015 Q3 | 2.72 Million USD | -10.7% |
| 2014 Q2 | 3.38 Million USD | 59.93% |
| 2014 Q3 | 2.63 Million USD | -22.34% |
| 2014 Q4 | 3.07 Million USD | 16.76% |
| 2014 Q1 | 2.11 Million USD | -37.6% |
| 2014 FY | 11.21 Million USD | -13.51% |
| 2013 Q3 | 3.39 Million USD | 9.74% |
| 2013 Q2 | 3.08 Million USD | 0.0% |
| 2013 FY | 12.96 Million USD | 51.45% |
| 2013 Q1 | 3.08 Million USD | 0.0% |
| 2013 Q4 | 3.39 Million USD | 0.18% |
| 2012 FY | 8.56 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 96.63 Million USD | 92.081% |
| AngioDynamics, Inc. | 303.91 Million USD | 97.482% |
| AtriCure, Inc. | 399.24 Million USD | 98.083% |
| Azenta, Inc. | 665.07 Million USD | 98.849% |
| BioLife Solutions, Inc. | 143.27 Million USD | 94.659% |
| The Cooper Companies, Inc. | 3.59 Billion USD | 99.787% |
| Daxor Corporation | 1.28 Million USD | -497.572% |
| Ekso Bionics Holdings, Inc. | 18.27 Million USD | 58.138% |
| Femasys Inc. | 1.07 Million USD | -613.826% |
| GlucoTrack, Inc. | - USD | -Infinity% |
| Harvard Bioscience, Inc. | 112.25 Million USD | 93.183% |
| Hologic, Inc. | 4.03 Billion USD | 99.81% |
| ICU Medical, Inc. | 2.25 Billion USD | 99.661% |
| Intuitive Surgical, Inc. | 7.12 Billion USD | 99.893% |
| KORU Medical Systems, Inc. | 28.51 Million USD | 73.168% |
| LeMaitre Vascular, Inc. | 193.48 Million USD | 96.045% |
| Innovative Eyewear, Inc. | 1.15 Million USD | -563.96% |
| Innovative Eyewear, Inc. | 1.15 Million USD | -563.96% |
| Masimo Corporation | 2.04 Billion USD | 99.626% |
| Microbot Medical Inc. | - USD | -Infinity% |
| Meihua International Medical Technologies Co., Ltd. | 97.09 Million USD | 92.119% |
| Merit Medical Systems, Inc. | 1.25 Billion USD | 99.391% |
| Nephros, Inc. | 14.23 Million USD | 46.256% |
| NovoCure Limited | 509.33 Million USD | 98.498% |
| NEXGEL, Inc. | 4.08 Million USD | -87.136% |
| NEXGEL, Inc. | 4.08 Million USD | -87.136% |
| Singular Genomics Systems, Inc. | 2.91 Million USD | -162.865% |
| OraSure Technologies, Inc. | 405.47 Million USD | 98.113% |
| Pro-Dex, Inc. | 53.84 Million USD | 85.789% |
| Pulse Biosciences, Inc. | - USD | -Infinity% |
| Predictive Oncology Inc. | 1.78 Million USD | -329.865% |
| Precision Optics Corporation, Inc. | 19.1 Million USD | 59.946% |
| QuidelOrtho Corporation | 2.99 Billion USD | 99.745% |
| Repligen Corporation | 638.76 Million USD | 98.802% |
| Sanara MedTech Inc. | 64.98 Million USD | 88.226% |
| STAAR Surgical Company | 322.41 Million USD | 97.627% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 50.22 Million USD | 84.764% |
| DENTSPLY SIRONA Inc. | 3.96 Billion USD | 99.807% |
| Jin Medical International Ltd. | 19.82 Million USD | 61.395% |